Monday, June 29, 2009

Bone marrow transplant suppresses AIDS in patient

Bone marrow transplant suppresses AIDS in patient

Wed Nov 12, 2008 9:06pm EST
BERLIN (Reuters) - A bone marrow transplant using stem cells from a donor with natural genetic resistance to the AIDS virus has left an HIV patient free of infection for nearly two years, German researchers.

The patient, an American living in Berlin, was infected with the human immunodeficiency virus that causes AIDS and also had leukemia. The best treatment for the leukemia was a bone marrow transplant, which takes the stem cells from a healthy donor's immune system to replace the patient's cancer-ridden cells.

Dr. Gero Hutter and Thomas Schneider of the Clinic for Gastroenterology, Infections and Rheumatology of the Berlin Charite hospital said on Wednesday the team sought a bone marrow donor who had a genetic mutation known to help the body resist AIDS infection.

The mutation affects a receptor, a cellular doorway, called CCR5 that the AIDS virus uses to get into the cells it infects.

When they found a donor with the mutation, they used that bone marrow to treat the patient. Not only did the leukemia disappear, but so did the HIV.

"As of today, more than 20 months after the successful transplant, no HIV can be detected in the patient," the clinic said in a statement.

"We performed all tests, not only with blood but also with other reservoirs," Schneider told a news conference.

"But we cannot exclude the possibility that it's still there."

The researchers stressed that this would never become a standard treatment for HIV. Bone marrow stem cell transplants are rigorous and dangerous and require the patient to first have his or her own bone marrow completely destroyed.

Patients risk death from even the most minor infections because they have no immune system until the stem cells can grow and replace their own.

HIV has no cure and is always fatal. Cocktails of drugs can keep the virus suppressed, sometimes to undetectable levels. But research shows the virus never disappears -- it lurks in so-called reservoirs throughout the body.

Hutter's team said they have been unable to find any trace of the virus in their 42-year-old patient, who remains unnamed, but that does not mean it is not there.

"The virus is tricky. It can always return," Hutter said.

The CCR5 mutation is found in about 3 percent of Europeans, the researchers said. They said the study suggests that gene therapy, a highly experimental technology, might someday be used to help treat patients with HIV.

(Reporting by Oliver Denzer; Writing by Maggie Fox in Washington; Editing by Vicki Allen)

© Thomson Reuters 2008. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world.

Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

Thursday, June 11, 2009

Tuesday, June 9, 2009

Growing Organs in the Lab

http://singularityhub.com/2009/06/08/growing-organs-in-the-lab/

Growing Organs in the Lab
Written on June 8, 2009 – 3:19 pm | by Drew Halley |
Why transplant an organ when you can grow yourself a new one?

This research isn’t something that might happen in the distant future. It’s being used today to grow fresh
organs, open up new ways to study disease and the immune system, and reduce the need for organ
transplants. Organ-farming laboratories are popping up across the planet, and showing impressive results.
Here we look at the state of the union of a rapidly advancing field called tissue engineering: what’s been
accomplished so far, and what’s right around the corner.
Patients who undergo organ transplants require loads of toxic drugs to suppress their immune systems;
otherwise their body might reject the organ. But tissue engineering could make organ transplants a thing of
the past. By using a patient’s cells to grow new types of tissue in the lab, researchers are finding new ways
to custom-engineer you new body parts by using your own cells.
At the cutting edge of organ engineering is Tengion, a clinical-stage biotech company based outside of
Philadelphia. Their most successful research to date led to the creation of the Neo-Bladder. Tengion takes
some of your cells and grows them in culture for five to seven weeks around a biodegradable scaffold.
When the organ is ready, it can be transplanted without the need to suppress the patient’s immune system
(because the organ was grown from the patient’s own cells, it carries no risk of rejection). Once the organ is
in, the scaffold degrades and the bladder adapts to its new (old) home.
The Tengion Neo-Bladder is in Phase II testing, meaning that they have already implanted the organ into
individuals and studied how the body adapts to it. After 5 years, the company was able to show that the
homegrown organs are safe and effective, capable of treating the bladder effects of spina bifida (a neural
tube defect that effects bladder function, among other things). After another round of Phase II trials, Tengion
will move on to Phase III testing; after that, the Neo-Bladder should be approved and be made commercially
available.
Atala wants to grow you an
organ
Tengion’s Neo-bladder is nearing the completion of its clinical trials, but they weren’t the first to grow one.
If anyone on Earth deserves the job title “Organ Farmer,” it’s Dr. Anthony Atala. He and his research team
at Wake Forest University Medical Center pioneered the world’s first lab-grown bladder, and they remain at
the forefront of the organ-growing field (Atala is also the chairman of Tengion’s scientific advisory board).
Wake Forest is the world’s largest regenerative medicine research center, and their current research is
growing 22 different types of tissue: heart valves, muscle cells, arteries, and even fingers.
So how many different types of human organs have been grown and transplanted? The lab-grown bladders
are among the only transplants of an entire organ, but a wide variety of partial organ transplants have taken
place. Skin cells are regularly grown in culture and grafted onto patients’ bodies. A graft was grown from a
patient’s trachea cells and transplanted to replace part of her airway that had degraded due to disease.
Cartilage has been grown and transplanted into a patient’s knee.
A number of technologies are under development but have yet to be transplanted into human bodies.
Recently, Dr. Nicholas Kotov and his lab at the University of Michigan have engineered artificial bone
marrow, a task that was previously doomed to failure. Kotov and his colleagues realized that in the body,
stem cell differentiation relies on chemical signals in three dimensions (whereas in a petri dish, it takes place
in two dimensions). This insight led to a new methodology that more closely replicated the natural
environment of stem cell differentiation in bone marrow tissue. The resultant homegrown marrow grew and
divided normally, even releasing antibodies in fight off an introduced influenza strain. It can be used to
study the role of bone marrow in fighting disease within the body, as well as creating a “bioreactor”:
harnessing the artificial marrow within a device to grow cells and tissues.
Tengion is pretty busy these days as well. Their new website lists a variety of new applications on the
horizon, including a Neo-Kidney augment, artery replacements (including in the heart), and variations on
their bladder technique to replace cancerous organs. Their company pipeline gives a general idea of the
relative stages of each project.
A number of initiatives are under way to create an artificial pancreas, which would revolutionize the way
we treat diabetes. By providing diabetics with a healthy pancreas, doctors could restore their natural control
of blood glucose by giving them an endogenous source of insulin. Anyone with experience of diabetes
knows the difficulty of manually monitoring and controlling your sugar levels, not to mention regularly
injecting insulin. A lab-grown pancreas replacement would be an incredible benefit to the 23.6 million
individuals in America alone who suffer from diabetes.
The Minnesota rat heart
As we previously reported, researchers at the University of Minnesota grew an entire rat heart in a
laboratory last year. Their next goal is to grow a pig heart, a significant milestone towards growing a human
heart due to their similar structure. Researchers hope to combine the scaffold of a pig heart with human
cardiac tissue to grow a hybrid heart suitable for transplant.
Another exciting frontier is the field of printable tissue and organs, which is just what it sounds like. Inkjet
cartidges are cleaned out and loaded with a mixture of live human cells and “smart gel.” Then, layer by
layer, the cells are printed atop one another until a 3D organ is constructed. Just as a normal printer can
deposit different colored ink, organ printing allows scientists to specify where to place different cell types.
Organ printing has already created beating cardiac cells, and could soon produce organs that are viable for
transplant. But unlike other 3D printers, I wouldn’t want this one in my living room.
The hottest areas in tissue growth are the types hardest to make: nerve, liver, kidney, heart and pancreas
cells. But these are precisely where Alata and Tengion are heading, pushing the industry into fresh territory.
Coupled with new regenerative treatments like Cook biotech’s foams and stem-cell organ patching, tissue
engineering will be keeping our organs young and healthy in the years to come.
Merely a decade ago, tissue engineering was still a new field that struggled to find funding and support.
Today, thousands of scientists worldwide are coordinating efforts to reach new breakthroughs, and the
demonstrated potential of these methods has helped bring in investors. That should keep the organ growing
field moving forward in the future months and years, and we’ll be covering new advances as they emerge.

Wednesday, May 6, 2009

Protein Controls Blood Vessel Formation, Offers New Drug Target

ScienceDaily (Dec. 5, 2007) — After an injury, the body grows new blood vessels to repair damaged tissue. But sometimes too much growth causes problems, as when new blood vessels in the eyes leak, causing diabetic retinopathy and blindness if not treated.

A protein called CIB1 discovered by researchers at the University of North Carolina at Chapel Hill School of Medicine appears to play a major role in controlling new blood vessel growth, offering a target for drug treatments to help the body repair itself after injury and control unwanted blood vessel growth.

"In the future, this knowledge may help our ability to control blood vessel growth in disease situations such as wound healing, retinal diseases and diabetes," said Leslie Parise, Ph.D., senior study author and professor and chair of biochemistry and biophysics in the UNC School of Medicine.

The results will appear in an upcoming print issue of the journal Circulation Research and were published online Nov. 1, 2007. The research was funded by the National Institutes of Health.

Parise's lab first discovered the protein, called CIB1 in 1997. It was originally found in blood platelets. CIB1 keeps blood platelets from sticking together, acting as a natural anti-coagulant to prevent clots that might lead to heart attacks or strokes. But further research showed CIB1 appears in almost every cell type in the body, Parise said. For example, male mice bred without both copies of the CIB1 gene are infertile.

In the current study, Parise and her colleagues found CIB1 in the endothelial cells that line all blood vessels. These cells jump-start new blood vessel growth via a process called angiogenesis. During angiogenesis, biological signals prompt endothelial cells to release enzymes and other chemicals that allow them to move away from existing blood vessels and form new ones.

While angiogenesis plays a critical role in embryo growth, CIB1 appears to only affect blood vessel growth after injury (sometimes called pathological or adaptive angiogenesis). Mice born without copies of the CIB1 gene survive and are reasonably healthy unless injured, Parise said.

"CIB1 appears to be an attractive drug target to control blood vessel growth since it does not play an essential role during fetal development but instead plays an important role in pathological forms of blood vessel growth," said first author and medical student at UNC Mohamed Zayed, Ph.D.

In experiments in mice missing CIB1 genes, the researchers found that CIB1 is critical for angiogenesis in the retina, as well as angiogenesis in hind legs. In both cases, the new blood vessel growth was prompted by ischemia, or restricted blood flow. However, clinicians treating retinal disease need to restrict blood vessel growth in the eyes, while patients with restricted blood flow in their limbs need to grow need blood vessels. Therefore, CIB1 could be a target for both pro- and anti-angiogenic drug therapies.

Parise notes that the lab is still determining the exact role CIB1 plays in angiogenesis. "We think it's involved in the chemical pathways that control blood vessel growth, such as signal transduction events," she said. It is also likely that CIB1 is one of many genes that contribute to angiogenesis during ischemia, inflammation and perhaps even tumor growth.

Study co-authors with Parise and Zayad include Weiping Yuan, Tina M. Leisner, Dan Chalothorn, Andrew W. McFadden, Michael D. Schaller, M. Elizabeth Hartnett and James E. Faber, all of UNC-Chapel Hill.

Fat Protein Cuts Blood Vessel Inflammation, May Help Heart, Scientists Find

ScienceDaily (June 4, 2007) — A natural substance secreted by fat cells can protect blood vessels from the damaging effects of inflammation, one of the factors that contribute to heart disease. Researchers at Jefferson Medical College have shown for the first time in an animal model that the substance – a protein called adiponectin – helps prevent immune system white blood cells from binding to the inside of blood vessel walls. Harnessing adiponectin’s properties, the scientists suggest, may someday help protect against the blood vessel damage so prevalent in patients with obesity and diabetes.

Reporting June 1, 2007 in the Journal of Clinical Investigation, researchers led by Barry Goldstein, M.D., Ph.D., professor of medicine and director of the Division of Endocrinology, Diabetes and Metabolic Diseases and Rosario Scalia, M.D., Ph.D., associate professor of molecular physiology and biophysics, both of Jefferson Medical College of Thomas Jefferson University in Philadelphia, discovered that mice lacking adiponectin had an increase in so-called “adhesion” molecules and high levels of white blood cells sticking to the inside of blood vessel walls, which are signs of inflammation. When they gave the animals the “active” piece of the normal adiponectin molecule for 10 days, inflammation in the blood vessels was greatly reduced.

“This is translational work,” says Dr. Scalia. “We’ve used a mouse model to prove conceptually what we see in a test tube system in isolated cells is relevant to an intact physiological system. It’s a necessary step before going to humans. These results suggest that perhaps restoring this protein could be important to preventing atherosclerosis and vascular disease.”

They used a technique, intravital microscopy, which permits researchers to illuminate blood vessels using fluorescent signals, enabling them to “see” reductions in white cells on the vessel wall and subsequent lessening in inflammation.

The scientists also looked at the effects of adiponectin on inflammation in normal mice. They gave mice a substance, TNF-alpha, which caused the release of inflammatory substances called cytokines. Injecting the mice with the active adiponectin-fragment reversed the effects of the cytokines and the resulting inflammation.

Inflammation is common in cardiovascular disease. Adiponectin has been shown in cells in culture to block some “adhesion molecules” and receptors that are necessary for white blood cells to interact with the vessel wall, explains Dr. Scalia. “This is the first study to show in animals that this is one of the key mechanisms involved in this protein’s anti-inflammatory effect on the vascular system,” he notes. “That suggests thinking about either activating the receptors of the target of this protein or administering the fragment.”

Adiponectin is the most abundant protein found in the bloodstream that originates from fat tissue, and circulates as large complexes. Low levels of adiponectin are associated with obesity, diabetes and heart disease. The fragment, called the globular domain, can function as an active, anti-inflammatory part, notes Dr. Goldstein. “The findings demonstrate clearly that the fragment has the active portions,” he says. “Since the globular domain is relatively easy to produce, it could eventually lead to clinical trials taking advantage of its effects in the vasculature in inflammation.”

“What’s novel about the work is that it’s in animals, and involves a specialized technique in Dr. Scalia’s laboratory in which you can visualize the interaction between the white blood cell and blood vessel wall,” says Dr. Goldstein.

Studying normal mice, Dr. Goldstein notes, is an important aspect of the work. While using genetically altered mice is crucial, animals completely lacking adiponectin don’t exactly mimic the human condition. Most obese individuals, for example, at least have low levels of adiponectin. Part of the work demonstrated that adiponectin also protected against vascular inflammation in normal mice, a result that helps to relate the findings to humans with increased risk of vascular disease.

Next, Dr. Scalia says, they would like to better understand how adiponectin prevents the increase in white blood cell-blood vessel “anchoring” molecules in disease conditions.

The group is also testing the effects of adiponectin in conditions mimicking diabetes by exposing cells in the laboratory and blood vessels in animals to high glucose levels. “High glucose also causes dramatic inflammatory changes in the blood vessel lining,” Dr. Goldstein says. “We’re working to determine whether adiponectin can also reverse these changes. This process is occurring in every patient with high blood sugars and we are hoping that adiponectin can reverse the adverse effects of glucose and protect the vessel wall from damage.”

White Blood Cells Can Sprout 'Legs' And Move Like Millipedes

http://www.sciencedaily.com/releases/2009/05/090504094424.htm

ScienceDaily (May 4, 2009) — How do white blood cells – immune system ‘soldiers’ – get to the site of infection or injury? To do so, they must crawl swiftly along the lining of the blood vessel – gripping it tightly to avoid being swept away in the blood flow – all the while searching for temporary ‘road signs’ made of special adhesion molecules that let them know where to cross the blood vessel barrier so they can get to the damaged tissue.

In research recently published in the journal Immunity, Prof. Ronen Alon and his research student Ziv Shulman of the Weizmann Institute’s Immunology Department show how white blood cells advance along the length of the endothelial cells lining the blood vessels. Current opinion maintains that immune cells advance like inchworms, but Alon’s new findings show that the rapid movement of the white blood cells is more like that of millipedes.

Rather than sticking front and back, folding and extending to push itself forward, the cell creates numerous tiny ‘legs’ no more than a micron in length – adhesion points, rich in adhesion molecules (named LFA-1) that bind to partner adhesion molecules present on the surface of the blood vessels. Tens of these legs attach and detach in sequence within seconds – allowing them to move rapidly while keeping a good grip on the vessels’ sides.

Next, the scientists turned to the Institute’s Electron Microscopy Unit. Images produced by scanning and transmission electron microscopes, taken by Drs. Eugenia Klein and Vera Shinder, showed that upon attaching to the blood vessel wall, the white blood cell legs ‘dig’ themselves into the endothelium, pressing down on its surface. The fact that these legs – which had been thought to appear only when the cells leave the blood vessels – are used in crawling the vessel lining suggests that they may serve as probes to sense exit signals.

The researchers found that the shear force created by the blood flow was necessary for the legs to embed themselves. Without the thrust of the rushing blood, the white blood cells couldn’t sense the exit signals or get to the site of the injury. These results explain Alon’s previous findings that the blood’s shear force is essential for the white blood cells to exit the blood vessel wall. The present study suggests that shear forces cause their adhesion molecules to enter highly active states. The scientists believe that the tiny legs are trifunctional: Used for gripping, moving and sensing distress signals from the damaged tissue.

In future studies, the scientists plan to check whether it is possible to regulate aggressive immune reactions (such as in autoimmune diseases) by interrupting the ‘digging’ of immune cell legs into the endothelium. They also plan to investigate whether cancerous blood cells metastasize through the blood stream using similar mechanisms in order to exit the blood vessels and enter different tissues.

Prof. Ronen Alon’s research is supported by the De Benedetti Foundation-Cherasco 1547. Prof. Alon is the incumbent of the Linda Jacobs Chair in Immune and Stem Cell Research.

Tuesday, May 5, 2009

Anger is in the genes

Being able to keep your cool or lose your temper is down to genes, according to a new study.
By Chris Irvine
Last Updated: 1:09AM BST 04 May 2009

Isolation of a gene called DARPP-32 helps explain why some people fly into a rage at the slightest provocation, while
others can remain calm.
More than 800 people were asked to fill in a questionnaire designed to study how they handle anger.

The German researchers also administered a DNA test to determine which of three versions of the DARPP-32 gene
people were carrying.
The gene affects levels of dopamine, a brain chemical linked to anger and aggression.
Those who had the "TT" or "TC" versions of the gene portrayed significantly more anger than those with the "CC" version.
The study, from the University of Bonn, also found that those who display more anger have less grey matter in the
amygdala, a part of the brain that helps keep our emotions balanced.
Martin Reuter, one of the researchers, who is a TC, said: "In other words, they are not able to control their feelings as well
as those without the mutation.
"I am not an angry person but I can get angry if it is important."
TT and TC versions are much more common in Western populations, with the researchers suggesting that demonstrations
of anger can help people get ahead in life.
"High degrees of anger are of course of low social desirability but a certain amount of dominance-related behaviour helps
to assert position in a social hierarchy," the researchers added.
Reporting in the journal Behavioural Brain Research, they added that genetics only account for around half of our
disposition towards anger, while DARPP-32 is one of several genes involved.
Earlier this year it was reported that showing anger rather than repressing emotions is the key to a successful professional
and personal life. The study by the Harvard Study of Adult Development found those who keep a check on their
frustrations are at least three times more likely to admit they have disappointing personal lives and have hit a glass ceiling
in their career.
© Copyright of Telegraph Media Group Limited 2009